Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cingulin-like protein 1 (CGNL1), also known as paracingulin, is a cytoskeletal junctional adaptor protein encoded by the CGNL1 gene and found predominantly at tight and adherens junctions in epithelial and endothelial cells. It plays a pivotal role in assembling and maintaining cell–cell junctions by regulating activities of small GTPases (notably RhoA and Rac1), which are essential for organizing the actin cytoskeleton and preserving epithelial barrier function. CGNL1's structural domains include a globular head, a central coiled-coil rod, and a tail; it can form dimers and interacts with proteins such as ZO-1 and PLEKHA7, enabling localized modulation of cytoskeletal elements and junctional stability. In endothelium, CGNL1 is important for focal adhesion formation, vinculin and paxillin recruitment, and angiogenesis by stabilizing VE-cadherin interactions. While rearrangements of the CGNL1 promoter can cause aromatase excess syndrome, CGNL1 is not considered a therapeutic target nor are there drugs known to interact with it. The gene is conserved across vertebrates, with functions primarily in cell junction dynamics and cytoskeletal regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cingulin-like protein 1 (CGNL1).